Hansa Biopharma AB (OSTO:HNSA) E10: kr-10.97 (As of Mar. 2026)


OSTO:HNSA Hansa Biopharma AB OSTO:HNSA
49 GF Score
Price kr33.10
GF Value kr24.55
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB E10?

Hansa Biopharma AB OSTO:HNSA -1.25% 49 E10 is kr-10.97 as of Mar. 2026. GuruFocus rates OSTO:HNSA with a GF Score™ of 49/100 and a GF Value™ of kr24.55 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Hansa Biopharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was kr-1.930. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr-10.97 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was -10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Hansa Biopharma AB was -10.30% per year. The lowest was -17.10% per year. And the median was -13.70% per year.

As of today (2026-06-29), Hansa Biopharma AB's current stock price is kr33.10. Hansa Biopharma AB's E10 for the quarter that ended in Mar. 2026 was kr-10.97. Hansa Biopharma AB's Shiller PE Ratio of today is .


Hansa Biopharma AB  (OSTO:HNSA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Hansa Biopharma AB E10 Related Terms


Hansa Biopharma AB E10 Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB E10 Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.52 -8.09 -9.22 -10.46 -10.85

Hansa Biopharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.45 -10.68 -10.78 -10.85 -10.97

OSTO:HNSA vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Hansa Biopharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Shiller PE Ratio falls into.


OSTO:HNSA
49GF Score
Hansa Biopharma AB OSTO:HNSA
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hansa Biopharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.93/133.3862*133.3862
=-1.930

Current CPI (Mar. 2026) = 133.3862.

Hansa Biopharma AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.940 101.019 -1.241
201609 -0.830 101.138 -1.095
201612 -0.980 102.022 -1.281
201703 -1.270 102.022 -1.660
201706 -1.280 102.752 -1.662
201709 -1.060 103.279 -1.369
201712 -1.340 103.793 -1.722
201803 -1.230 103.962 -1.578
201806 -1.550 104.875 -1.971
201809 -1.610 105.679 -2.032
201812 -2.090 105.912 -2.632
201903 -1.810 105.886 -2.280
201906 -2.060 106.742 -2.574
201909 -2.360 107.214 -2.936
201912 -2.770 107.766 -3.429
202003 -2.330 106.563 -2.916
202006 -2.480 107.498 -3.077
202009 -2.770 107.635 -3.433
202012 -2.370 108.296 -2.919
202103 -2.340 108.360 -2.880
202106 -2.980 108.928 -3.649
202109 -3.340 110.338 -4.038
202112 -3.680 112.486 -4.364
202203 -3.110 114.825 -3.613
202206 -3.820 118.384 -4.304
202209 -3.450 122.296 -3.763
202212 -3.210 126.365 -3.388
202303 -3.920 127.042 -4.116
202306 -4.790 129.407 -4.937
202309 -4.766 130.224 -4.882
202312 -2.360 131.912 -2.386
202403 -4.150 132.205 -4.187
202406 -3.300 132.716 -3.317
202409 -1.530 132.304 -1.543
202412 -4.080 132.987 -4.092
202503 -0.570 132.825 -0.572
202506 -2.530 133.699 -2.524
202509 -1.750 133.482 -1.749
202512 -1.620 133.386 -1.620
202603 -1.930 133.386 -1.930

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr-10.97 mean?
Hansa Biopharma AB (OSTO:HNSA) has a E10 of kr-10.97 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's E10 too high?
Hansa Biopharma AB's current E10 is kr-10.97. Overall, Hansa Biopharma AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's E10 compare to VRTX and REGN?
Hansa Biopharma AB's E10 of kr-10.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current E10 is kr-10.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.55, compared to a current price of kr33.10 — trading 34.8% above its estimated fair value. The current E10 is kr-10.97. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current E10 is kr-10.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr33.10 is trading 34.8% above its estimated GF Value™ of kr24.55. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:HNSA:

  • E10: kr-10.97
  • GF Value™: kr24.55 vs. price of kr33.10 (34.8% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score

Get the complete analysis for OSTO:HNSA

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr33.10
Price
kr24.55
GF Value